Authors: Rachael A. Clark
Published: 2023-12-01
DOI: 10.1126/sciimmunol.adn0649
Source: Full article
Immune responses to gut bacteria are associated with development of type 1 diabetes and predict the effectiveness of teplizumab, an anti-CD3 antibody, in delaying diabetes onset.